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ABSTRACT 
Objectives 
 To compare the effectiveness of risk of malignancy index 1 and 2 to 
differentiate between benign and malignant ovarian tumors. 
 Methodology 
        CA 125 level was done by ECLIA <Enzyme chemi luminescent  
Immunoassay>. In my study based on ultrasound features, menopausal status, and CA 
125 levels RMI 1 & RMI 2 scoring is calculated in women above age 40 years with 
ovarian tumors. Ultrasound findings were scored with one point for each of the following 
: mutilocular cyst , evidence of solid areas , evidence of metastasis, presence of ascites, 
bilateral lesions (zero points for women with no abnormality, one point for women with 
one abnormality, in women with two or more abnormality 3 points given in RMI 1 , 4 
points given in RMI 2). Menopausal status is graded as follows : premenopausal status is 
graded M = 1 , postmenopausal status is graded as M=3 in RMI 1 , M=4 in RMI 2 .  
RESULTS: 
In my study RMI 2 has the advantage over RMI 1 to differentiate benign and 
malignant ovarian tumors. Cut off value to differentiate benign and malignant tumors was 
200. Sensitivity and negative predictive value is 100% for both RMI 1 & RMI 2. 
                                                        
Specificity of RMI 2 is 52.5%, for RMI 1 is 47.5%.Positive predictive value of RMI 1 is 
32.26%, RMI 2 is 34.48%. Accuracy of RMI 1 IS 58%,for RMI 2 is 62%. 
CONCLUSION: 
RMI 2 is simple scoring system which is more reliable to identify malignant 
ovarian tumors. Preoperative evaluation by using this scoring system helps to avoid 
unnecessary surgical intervention.  
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                                                                                         INTRODUCTION 
                                                        
The ovaries are a pair of integral organs belonging to the female reproductive 
system. Cancer of the ovary which is common in postmenopausal women, is the fifth 
most common malignancy affecting women and second most common gynaecological 
malignancy next to ca endometrium.  
However, the most common cause of death from gynaecological malignancy is 
associated with ovarian carcinoma. If diagnosed and treated early, ovarian malignancies 
may show a favourable prognosis.  
However, the major hurdle faced by gynaecologists is in diagnosing the disease 
early owing to the fact that ovarian malignancies do not manifest clinically until a later 
stage, when the prognosis becomes poor. Hence, a high degree of suspicion and 
multidiagnostic approach is required in patients with nonspecific symptoms in the high 
risk age group, to detect the malignancy at its earliest. 
 
 
 
 
 
 
 
                                                        
 
 
 
 
 
 
 
 
 
 
                       
 
              
 
 
                                                                               AIMS & OBJECTIVES 
                                                        
AIM OF THE STUDY: 
 To identify the ability of RMI 1 and RMI 2 to differentiate between benign and 
malignant ovarian tumors. 
OBJECTIVES OF THE STUDY: 
                      This study is undertaken mainly to identify women at risk of malignant 
ovarian tumor to avoid unnecessary surgical intervention. Women aged above 40 years 
admitted with ovarian tumor has included in this study. Three main determinants are 
menopausal status, ultra sound feature, CA 125 levels.  
 
 
 
  
 
 
                                
                                                                                                                                                                                 
 
                                                        
 
 
 
 
 
 
 
 
                                                                                                                                        
 
 
 
                                                 
              
 
                                                                                          REVIEW OF LITERATURE 
                                                        
 Morgante et al. in a retrospective study, which revealed that RMI 2 was more 
reliable with 81% sensitivity and 90% specificity. His study involving 47 
patients showed that patients operated on by a gynecological oncologist had a 
24% improvement in 5 year survival over those patients operated on by general 
gynecologists.  
 Ulusoy et al. in a study done on 296 women, in which cut off level to 
differentiate benign and malignant tumor was 153. 
 Obeidat et al. in a retrospective study on 100 women with pelvic masses 
admitted for laparotomy found that RMI diagnosed malignancy more accurately 
than any single criterion.  
 Sharon et al.  performed a retrospective review of  medical records of 163 patients 
and found that using a cut-off of 120, the first RMI definition(RMI 1) had 72% 
sensitivity and 87% specificity; the second (RMI 2) had 76% sensitivity and 81% 
specificity. 
 
              Ovarian cancer is a common, deadly gynecologic malignancy worldwide, 
usually diagnosed late due to its lack of symptoms and low specificity of screening tests. 
Among Indian females, ovarian cancer is one of the common cancer to present at an 
advanced stage. In Japan and Asian countries, 2–6. 5 new cases per 100,000 women per 
year have been reported. In women over 30 years of age, ovarian carcinoma is the sixth 
commonest cancer and the fourth commonest cause of death. 
                                                        
           Ovarian cancer patients have better outcomes when treated in tertiary centers by a 
team led by gynecological oncologist.  When a prompt referral to such centres is not 
achieved early, complication rates are higher (~30%) and Survival outcomes are lower 
(~10%).  CA 125, well-known tumor marker used in the risk assessment of ovarian 
cancer is positive in 80% of patients. CA 125 can be negative in 30% - 50% of patients 
with stage 1 ovarian cancer 
        Differentiating benign from malignant ovarian lesions in the absence of surgical 
exploration and HPE report is not easy. Most of the malignant ovarian tumors diagnosed 
after menopause. Survival rate in stage 3 is 27% and 16% in stage 4. Most of the ovarian 
tumors diagnosed at an advanced stage because of its atypical presentation.  
USG has 62% sensitivity and 73% specificity to diagnose malignant ovarian 
tumor.85% epithelial ovarian cancer has elevated CA125 level. RMI scoring system 
developed to improve the diagnostic quality of ovarian tumors.  
In 1990, RMI 1 scoring system was first developed by Jacob et al, it has the 
sensitivity of 85.4% and specificity of 96.9% to differentiate benign and malignant 
ovarian tumors.  
RMI 2 scoring system was developed by Tingulstad et al in 1996, it was found to 
be better than RMI 1 to identify benign and malignant ovarian tumors.      
If the full surgical staging procedure is carried out initially by a trained 
gynecological oncologist, women with ovarian malignancy have shown to have better 
prognosis. A preoperative knowledge of the nature of the adnexal mass is needed to 
optimally plan surgery at the time of initial treatment. The risk of malignancy index 
                                                        
(RMI) has been shown to be a triage tool with the potential to reduce the workload in a 
busy gynecological unit. 
PATHOLOGY: 
         Histology of ovarian tumors presents wide variations and may be grouped as 
follows:  
         1.  Epithelial (80–90%) 
         2.  Non epithelial (10-20%) 
RISK FACTORS FOR OVARIAN CANCER  
 Age - 45-60 years  
Nulliparous or low parity  
Women with previous PCOS, or on tamoxifen  
High calorie, high fat diet  
Genetic predisposition – BRCA 1 & 2 genes  
Late menopause  
Breast and GIT cancer 
Prolonged HRT in menopause women  
EPITHELIAL CANCERS OF THE OVARY             
Histologically 
                                                        
75%-serous  
   20%- mucinous 
   2%- endometrioid 
   1% or less-Brenner tumor, clear cell carcinomas and undifferentiated cancers.   
 
    Each tumor type has a histologic pattern similar to a part of the upper genital tract, e.g. 
serous or papillary pattern -fallopian tube lining, mucinous tumors-endocervical glands 
and the endometrioid tumors-endometrium.  
  Nearly 50% benign serous epithelial tumors undergo secondary malignant change, 
compared to only 5% in mucinous cysts. Borderline tumors has low malignant potential 
which occur mostly in the premenopausal age group. Invasive cancers common among 
postmenopausal women which was spread rapidly.  
SEROUS CARCINOMA  
             Stromal invasion is present in malignant serous tumor. Papillary and glandular 
structures seen in low grade tumor. Mitotic activity and nuclear pleomorphism 
predominantly seen in malignant serous tumor. Serous psammocarcinoma is a rare 
variant in which 75% of epithelial nests are associated with psammoma body formation. 
 
 
 
                                                        
 
  SEROUS TUMOURS OF OVARY 
 
 
 
 
MUCINOUS CARCINOMA 
It may grows larger in size , sometimes occupying the entire abdominal cavity. 
Typical histological features shows loculi which was lined by mucin secreting 
epithelium.  
 
                                                        
                         
 
                 MUCINOUS TUMOURS OF OVARY  
 
 
BORDERLINE MUCINOUS TUMORS 
 This type of tumor was very difficult to diagnose. Multiple sections from many 
areas in mucinous tumor was taken to diagnose this tumor.  
 
 
 
 
                                                        
PSEUDOMYXOMA PERITONEI 
 This tumor is characterized by abundant gelatinous material in the abdominal 
cavity which was surrounded by fibrous tissue. Most commonly associated with 
appendiceal mucinous neoplasm and also associated with mucinous ovarian neoplasm. 
ENDOMETRIOID TUMORS  
It has complex glandular pattern with all the potential variations of epithelium 
found in the uterus. Borderline endometriod tumor may resemble an endometrial polyp or 
complex endometrial hyperplasia. 
                              ENDOMETRIOID CARCINOMAS 
     
 
                                                        
MULTIFOCAL DISEASE  
 Around 20% cases of endometriod carcinoma of ovary is associated with 
endometrial carcinoma. Patients had only 40%-50% survival when metastases from 
uterus to ovaries is present. Multifocal disease is identified based on the histological 
pattern of the tumor.    
CLEAR CELL CARCINOMAS 
 Clear cells and hobnail cells are present in the clear cell carcinomas. Focal areas of 
endometriosis also present.  
 
TRANSITIONAL CELL CARCINOMA  
This tumor pattern resembling the transitional cell carcinoma of the urinary 
bladder. It has good prognosis and sensitive to chemotherapy. 
PERITONEAL CARCINOMAS 
In this type tumor ovaries are normal or minimally involved. Involvement of 
uterosacral ligaments, pelvic peritoneum, omentum is predominantly seen. Borderline 
serous peritoneal tumor has good prognosis. Less common type is peritoneal 
endometrioid carcinoma. These tumors considered clinically similar as ovarian or 
fallopian tube cancers. 
MESOTHELIOMAS 
 These tumors appears clinically as multiple intraperitoneal masses. Usually entire 
peritoneum is involved.  It is not related asbestos exposure in women.      
 
                                                        
CLINICAL FEATURES 
 80% of epithelial ovarian cancers seen in postmenopausal women. Most of the 
tumors in postmenopausal women are malignant. Common age group around 56 – 60 
years. These cancers rare in less than 45 years of age. Germ cell tumors common among 
women with age less than 21 years. 
 
PREVENTION 
Parity has the inverse relationship with risk of ovarian tumors. Use of OCP 
reduces the risk of ovarian cancers. OCP use more than 5 years reduce their relative risk 
to 0.5%. while counselling the patient regarding contraception, have to explain the 
benefits of OCP. Prophylactic salphingo-oophorectomy reduces the risk of nonuterine 
pelvic cancers. Ovaries provide protection against cardiovascular disease and 
osteoporosis.   
  
SCREENING 
Screening with transvaginal USG in postmenopausal women is recommended. It 
has high sensitivity in detecting the early stage ovarian cancers. Trans vaginal colour 
flow Doppler is not useful for screening. CA 125 is not useful tool for screening but it is 
used during chemotherapy to monitor the response of the treatment.  
 
 
 
                                                        
GENETIC RISK FOR EPITHELIAL OVARIAN CANCER 
 Life time risk of ovarian cancer in the US is about 1.4%. Risk is higher in women 
with strong family history.  
HEREDITARY OVARIAN CANCER 
BRCA 1 & BRCA 2 
 Mutation in BRCA 1 gene which is located in chromosome 17, commonly seen in 
hereditary ovarian cancers. Only few malignancy is associated with BRCA 2 mutation 
which is located in chromosome 13. BRCA 1 and BRCA 2 associated with both breast 
and ovarian tumors. Lynch syndrome inherited as autosomal dominant, higher chance of 
ovarian and endometrial carcinoma. The life time risk of having ovarian tumors in 
women with BRCA 1 is 28%-44%, which is 27% for in women with BRCA 2 mutation. 
Ovarian tumors occurs earlier in this syndrome. Breast cancers may be bilateral.   
    
MANAGEMENT OF WOMEN AT HIGH RISK FOR OVARIAN CANCER 
 Management of ovarian tumors depends on the age, reproductive plans, extent of 
risk. Histological diagnosis of the family members ovarian cancer should be verified. 
National institutes of health consensus conference on ovarian cancers recommends, the 
value of screening with trans vaginal ultrasonography , CA 125 levels, is not established 
in high risk groups. Most effective way to reduce the risk is doing bilateral salphingo- 
oophorectomy.   
 
 
                                                        
PROPHYLACTIC SALPHINGO-OOPHORECTOMY IN HIGH RISK WOMEN 
 It reduce the risk of BRCA related gynaecological cancer by 96%. Role of 
hysterectomy in prevention of ovarian cancers is questionable. Women on tamoxifen 
benefits from performance of hysterectomy with bilateral salphingo-oophorectomy 
because tamoxifen intake is associated with risk of benign endometrial lesions.  
 
SYMPTOMS 
Most of the women have vague and nonspecific symptoms. Heavy or irregular 
menstrual bleeding seen in premenopausal age group women. Prseeure symptoms like 
increased frequency and constipation seen while mass compressing against the the rectum 
and bladder. Rarely lower abdominal pain and dyspareunia is seen. Other symptoms 
includes abdominal distension, bloating, constipation, nausea, anorexia, early satiety. 
Postmenopausal women may presented with vaginal bleeding.   
 
SIGNS 
 Presence of pelvic mass which solid, fixed and irregular is the most important 
sign. Any palpable pelvic mass in postmenopausal women is considered to be malignant 
which is known as the postmenopausal palpable pelvic syndrome. 
DIAGNOSIS 
To differentiate malignant from benign ovarian masses CA 125 levels are useful. 
Postmenopausal women with adnexal mass and high serum CA 125 level has PPV of 
                                                        
96% for malignancy. Specificity of the test is low in case of premenopausal women 
because elevataed CA 125 levels commonly associated with benign conditions.  
An interval of atleast two months is allowed, during which hormonal suppression 
with an OCP may be used. Regression of non neoplastic lesions monitored by pelvic 
examination and USG. If there is no change in the size of the mass or any increase in size 
should be considered as neoplastic mass which should be removed by surgery. Most of 
the bilateral tumors to be malignant. In USG , malignant tumors has the following 
features like, areas of complexity, irregular borders, multiple echogenic pattern within the 
mass and dense multiple irregular septae. Better resolution obtained by trans vaginal 
sonography. Specificity of USG enhanced by colour flow Doppler. Exploratory 
laparotomy is needed to diagnose the ovarian cancer. Preoperative assessment done to 
exclude other primary cancers metastatic to the ovary. A Pap test is done ,eventhough it 
has very low detection rate for ovarian cancer. Endocervical biopsy taken in case of 
patients with irregular menstrual bleeding or postmenopausal vaginal bleeding.    
 
SPREAD OF THE TUMOR 
Mode of spread of epithelial ovarian cancers includes haematogenous, lymphatic 
and exfoliation of cells into the peritoneal cavity. 
 
TRANSCOELOMIC SPREAD 
 Exfoliation of cells along the surface of the peritoneal cavity is the most common 
mode of spread of the tumor. Most common sites of metastases includes posterior cul-de-
                                                        
sac, paracolic gutters, liver capsule, right hemidiaphragm, peritoneal surface of intestine, 
mesenteries, omentum. Functional intestinal obstruction known as the carcinomatous 
ileus, in which tumor agglutinates the loops of bowel.  
 
 
            TUMOUR SPREAD TO BLADDER & LARGE INTESTINE  
 
                                                        
 
LYMPHATIC SPREAD  
 In advanced stage disease involvement of pelvic and para aortic lymph nodes is 
common. Supra clavicular lymph node involvement rarely seen in some conditions. 
 
HEMATOGENOUS SPREAD  
 Only 2% to 3% of patients had involvement of vital organ parenchyma such as 
liver and lungs. At the time of diagnosis hematogenous dissemination is uncommon.  
NONEPITHELIAL MALIGNANCIES OF THE OVARY 
The details of these types are as follows:  
1. DYSGERMINOMA   
   2. TERATOMA 
 (A) Mature , Dermoid Cyst 
(B) Immature— Solid/Cystic  
 (C) Monodermal teratomas - Struma Ovarii, Carcinoid, Mixed and Others  
   3. ENDODERMAL SINUS TUMOUR   
   4. EMBRYONAL CARCINOMA 
   5. POLYEMBRYOMA 
  6. CHORIOCARCINOMAS  
  7. MIXED FORMS. 
 
                                                        
ENDODERMAL SINUS TUMOR 
         Endodermal sinus (yolk sac) tumor though rare, is the second most common of 
germ cell origin originating from a multipotentia embryonal tissue,with selective 
differentiation of yolk sac elements. This is why the tumor is rich in alpha-fetoproteins 
and alpha-l-antitrypsin. Histologically, it presents with papillary projections composed of 
a central core of blood vessels enveloped by immature epithelium. Intracellular and 
extracellular hyaline droplets are present in all tumors. The alpha-fetoprotein content can 
be stained by immune peroxidase techniques. Most of these patients are children or 
young women, presenting with abdominal pain and a pelvic mass. They are rapidly 
growing tumors. Although they are highly malignant, they respond to chemotherapy with 
good survival rate. 
CHORIOCARCINOMA  
Part of a mixed germ cell tumor. Its origin as a teratoma can be confirmed in 
prepubertal girls, when the possibility of its gestational origin can be definitely 
excluded. The tumors have high vascularity. Histologically, it shows a dimorphic 
population of syncytiotrophoblasts and cytotrophoblasts. It secretes large quantities of 
human chorionic gonadotropin, which forms an ideal tumor marker in the diagnosis 
and management of the tumor. The tumor is highly malignant, and metastasizes by 
blood stream to the lungs, brain, bones and other viscera.  
 
                                                        
EMBRYONAL CELL CARCINOMA  
             Embryonal cell carcinoma is a rare tumor accounting for about 5% of all germ 
cell tumors, and occurring in prepubertal girls, secretes both alpha-fetoproteins and 
chorionic gonadotropins. It is associated with symptoms of precocious puberty and 
menstrual irregularities. It is highly malignant. The condition may be associated with 
fever due to torsion, rupture and haemorrhage. Although 20–25% of all ovarian 
neoplasms are germ cell tumors, only 3–5% are malignant. Dysgerminoma and pure ger-
minomas secrete lactose dehydrogenase. Dysgerminomas are highly radiosensitive. They 
also respond well to chemotherapy without interfering with future fertility and therefore 
chemotherapy is preferred.  
 
              DYSGERMINOMA OF OVARY  
 
 
                                                        
SEX CORD STROMAL TUMORS  
Sex cord stromal tumors are either benign or malignant. They account for about 5–
8% of all ovarian malignancies. These tumors are composed of various combinations of 
cells consisting of granulosa cells, theca cells, sertoli and leydig cells as well as 
morphologically indifferent cells. They are also called mesenchymomas.  
 
GRANULOSA CELL TUMORS 
Granulosa cell tumors secrete estrogens. Depending on the age of their 
appearance, they may cause precocious puberty, menometrorrhagia and episodes of 
abnormal uterine bleeding are common in women of childbearing age and 
postmenopausal bleeding in elderly women. Endometrial hyperplasia occurs in 25–50% 
of patients, and endometrial carcinoma occurs in about 5% of cases, more likely with 
theca cell tumor. A granulosa cell tumor secretes inhibin, which is a marker for this 
tumor.  
 
 
 
 
 
 
 
                                                        
 GRANULOSA CELL TUMOUR 
  
  
 
SERTOLI LEYDIG CELL TUMORS  
Androblastomas or arrhenoblastomas commonly occurring in the third and fourth 
decades of life are very rare and account for 0.2% of all ovarian neoplasms. They secrete 
androgens which can cause defeminization followed by masculinization. The women 
experiences oligomenorrhoea followed by amenorrhoea, flattening of the breasts, acne, 
hirsutism, enlargement of the clitoris and finally a change in voice. On removal of the 
tumor, all the above changes reverse except voice change.  
SARCOMA  
             Ovarian sarcomas are rare. Many tumors labelled as sarcomas have been 
misdiagnosed histologically and in reality, they are granulosa cell tumors or anaplastic 
                                                        
carcinomas. Sarcomas arise most frequently after menopause, particularly in multipara. 
They give rise to multiple metastases.  
 MANAGEMENT  
 The operable cases (Stages I and II) should undergo total hysterectomy and 
bilateral salpingo-oophorectomy with omentectomy.  
Advanced,inoperable case (Stages III and IV) will benefit from debulking surgery 
and tumor removal. Postoperative chemoradiation improve the survival and quality of 
life. Surgery provides symptomatic relief and reduces the amount of malignant tissue to 
be subjected to chemotherapy .Smaller residual tissue responds better to chemotherapy 
and thus remission period and survival is improved. Pre-operative cisplatin followed by 
surgery is lately employed. 
Postoperative chemoradiation depend upon the staging and type  of  tumor . The 
duration of chemotherapy is decided by the level of tissue markers.  
INTERVAL SURGERY  
Some advanced and bulky tumors are initially treated with chemotherapy for 3 
cycles,followed by a debulking surgery and a postoperative chemotherapy as dictated 
by tissue marker.  
Laparoscopic surgery, if undertaken, may have the following disadvantages:  
1. Possibility of spillage during surgery with recurrence.  
                                                        
2. Port-site metastasis in 1–1.5% cases,which can be reduced by use of endospecimen 
bag, lavage and use of intraperitoneal chemotherapy.  
 
SECOND LOOK SURGERY 
1. To detect the presence of  any  residual  tumor  following a planned course 
of chemotherapy and decide if further chemotherapy is required. The availability of 
tissue markers for vast majority of ovarian tumors in the follow-up, have decreased 
the importance of second-look surgery and surgical morbidity is also eliminated. Be-
sides, microscopic residual tumors may not be detected at laparoscopy. 
       2. Following a 3–6 month course of chemotherapy in an inoperable case, second-
look surgery may enable TAH and BSO or debulking procedure.  
          3. In a recurrent tumor.  
          4.  Instead of laparotomy, second-look laparoscopy is another alternative.  
Combination of surgery, radiotherapy and chemotherapy has enhanced the survival rate 
and quality of life considerably.  
  
Recurrent tumor – 
 Treatment modality in case of recurrent tumour is based upon the type of tumor, 
size and its histology.  
- Second-look surgery and removal of the lesion—for a single-site recurrence.  
- Chemotherapy—for visceral metastasis.  
                                                        
- Radiotherapy—preferably for nodal metastasis.  
 
Intraperitoneal chemotherapeutic drug may be instilled in a small residual tumor, at the 
end of surgery.   
Stem cell therapy may have a role in future. Dysgerminoma and granulosa cell tumor 
respond well to both chemotherapy and radiotherapy. In a young woman, fertility-
retaining surgery of unilateral ovariotomy is followed by chemotherapy as radiotherapy 
destroys the other ovary. In older woman,radiotherapy can be given following 
hysterectomy and salpingo-oophorectomy. 
 
 
 
PRIMARY CHEMOTHERAPY  
Advanced malignancy is considered relatively sensitive to cytotoxic agents and the 
duration of survival among patients has increased over the past two decades, yet, fewer 
than 20 percent can be cured.  
INTRAVENOUS CHEMOTHERAPY  
Platinum-based chemotherapy is the mainstay systemic treatment of ovarian 
cancer. The most widely used regimen in the  US is six courses of carboplatin and 
paclitaxel. Additional cycles required to achieve clinical remission suggests relative 
                                                        
tumor chemoresistance and usually leads to an earlier relapse. Addition of a third 
cytotoxic agent has been reported to further improve outcome.  
INTRAPERITONEAL CHEMOTHERAPY 
In January 2006, the national cancer institute issued a rare clinical announcement 
encouraging the use of intraperitoneal chemotherapy. The median duration of overall 
survival was 66 months in the iv/ip group compared with 50 months in the intravenous 
treatment group. Despite this dramatic improvement in survival, many clinicians still 
consider ip chemotherapy to be an experimental treatment. 
MANAGEMENT OF PATIENTS IN REMISSION  
In most women with advanced ovarian cancer, surgery plus platinum-based 
chemotherapy will result in clinical remission. However, up to 80 % will relapse 
eventually and die from disease progression. Lower CA125 levels generally are 
associated with fewer relapses and longer survival. Since most patients achieving 
remission will have residual, clinically occult, drug-resistant cells, several options are 
appropriate to consider, but there is no concrete proof that any intervention is beneficial.  
SURVEILLANCE  
After completion of treatment, patients should be regularly followed up with 
examinations and CA125 determinations. To monitor advanced ovarian cancer patients, 
                                                        
imaging tests may be indicated more frequently and a heightened suspicion for relapse 
should be maintained. 
RADIATION THERAPY  
In the US, when compared to Europe, patients in remission after primary therapy 
are rarely treated with whole abdominal radiotherapy due to doubtful benefit and fear of 
excessive toxicity. However, the long-term effectiveness of this consolidation strategy is 
comparable with that achieved with other modalities of treatment. As a result, it may be 
considered for selected patients with microscopic disease detected at second-look 
surgery.  
MANAGEMENT OF RECURRENT OVARIAN TUMOR  
Gradual elevation in levels of CA125 is usually the first sign of relapse. In such 
cases tamoxifen may be administered frequently since it has some activity in treating 
recurrent disease with minimal toxicity. Without treatment, the recurrence usually will 
become obvious clinically within 2 to 6 months, mostly within the abdomen. Women 
who progress during primary chemotherapy are classified as having platinum-refractory 
disease .Those who relapse within 6 months have platinum-resistant ovarian cancer. 
Patients in either category have a poor prognosis, and palliative nonplatinum 
chemotherapy is effectively the only option. Women who relapse more than 6 to 12 
months after completion of primary therapy are considered platinum-sensitive.  
                                                        
PALLIATION OF END STAGE OVARIAN CANCER  
During treatment, intermittent episodes of partial small and large bowel 
obstruction are common, which may be worse in those with recurrent disease.Bowel 
obstruction that does not resolve with nasogastric suction can be managed aggressively 
with surgical intervention, initiation of total parenteral nutrition (TPN), and continued 
chemotherapy. Ideally, a colostomy, ileostomy, or intestinal bypass will return reasonably 
normal bowel function. Unfortunately, a satisfactory surgical result is often not possible 
because of multiple sites of partial or complete obstruction. In addition, successful 
palliation is rarely achieved when the transit time is prolonged by diffuse peritoneal 
carcinomatosis or when the anatomy requires a bypass that results in the short bowel 
syndrome. Further, recovery may be complicated by an enterocutaneous fistula, 
reobstruction, or other morbid event. For some patients, a refractory bowel obstruction 
can be managed by placement of a palliative gastrostomy tube, IV hydration, and hospice 
care. In a woman with symptomatic, rapidly reaccumulating ascitic fluid, repeated 
paracenteses or placement of an indwelling peritoneal catheter will provide symptomatic 
relief. Similarly, a refractory malignant pleural effusion can be managed by thoracentesis, 
pleurodesis, or placement of indwelling pleural catheter. Although these procedures and 
others may be appropriate in selected patients, the inability to halt disease progression 
should be acknowledged. In addition, any intervention has the potential to result in an 
unanticipated catastrophic complication. Overall, palliative procedures are used most 
compassionately when incorporated into the overall treatment plan.  
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                       MATERIALS AND METHODS 
                                                        
SOURCE OF DATA: 
             A total of 50 women who attended the gynecology clinic of the department of 
obstetrics and gynecology at Coimbatore medical college hospital as well as those 
admitted in the ward were selected for the study. 
STUDY PERIOD: 
June 2017 TO June 2018. 
STUDY DESIGN: 
Comparative Prospective study. 
STUDY SUBJECTS: 
Sample size: 50 
INCLUSION CRITERIA: 
1. Women aged above  40 years 
 2. Women presenting as adnexal mass and admitted for evaluation and treatment       
EXCLUSION CRITERIA:   
        1. Age less than 40 years 
        2. Women already diagnosed of ovarian malignancy and received chemotherapy for 
the same 
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
         
               
                                                                                                       OBSERVATIONS 
                                                        
                                                              RESULTS 
 
HISTOPATHOLOGY EXAMINATION 
 
NO OF PATIENTS PERCENTAGE 
MALIGNANT 10 20% 
BENIGN 40 80% 
 
 
 
 
 
 
20% 
80% 
HPE 
MALIGNANT
BENIGN
                                                        
 
AGE DISTRIBUTION 
 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
MORE THAN 50 28 56% 
LESS THAN 50 22 44% 
 
 
 
 
 
 
 
28 
22 
AGE IN YEARS 
MORE THAN 50 LESS THAN 50
                                                        
AGE VS HPE 
AGE IN YEARS MALIGNANT BENIGN 
MORE THAN 50 10 18 
LESS THAN 50 0 22 
   CHI SQUARE TEST 
P VALUE - 0.002 
SIGNIFICANT 
 
 
 
 
In my study out of 50 patients women with more than 50 years, 10 patients had malignant 
ovarian tumors. P value is 0.002.  
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MENOPAUSAL STATE 
 
MENOPAUSE NO OF PATIENTS PERCENTAGE 
POSTMENOPAUSAL 29 58% 
PREMENOPAUSAL 21 42% 
 
 
 
 
 
 
 
58% 
42% 
MENOPAUSAL STATE 
POSTMENOPAUSAL
PREMENOPAUSAL
                                                        
MENOPAUSAL STATE VS HPE 
MENOPAUSE MALIGNANT BENIGN 
POSTMENOPAUSAL 10 19 
PREMENOPAUSAL 0 21 
   CHI SQUARE TEST
P VALUE - 0.003 
SIGNIFICANT 
 
This picture depicts relationship between menopausal status and HPE correlation of 
ovarian tumors. 
 
Out of 50 patients 10 postmenopausal women had malignant ovarian tumor. Significant p 
value is 0.003. 
1
0
 
1
9
 
0
 
2
1
 
M A L I G N A N T  B E N I G N  
MENOPAUSAL STATE VS HPE 
POSTMENOPAUSAL PREMENOPAUSAL
                                                        
                                                     CA – 125 LEVELS 
 
CA – 125 NO OF PATIENTS PERCENTAGE 
MORE THAN 35 43 86% 
LESS THAN 35 7 14% 
 
 
 
 
 
 
 
86% 
14% 
CA - 125 LEVEL 
MORE THAN 35
LESS THAN 35
                                                        
CA -125 LEVEL VS HPE 
CA - 125 MALIGNANT BENIGN 
MORE THAN 35 10 33 
LESS THAN 35 0 7 
   CHI SQUARE TEST 
P VALUE - 0.154 
NON SIGNIFICANT 
 
 
 
 
 
 
10 
33 
0 
7 
0
5
10
15
20
25
30
35
MALIGNANT BENIGN
CA 125 LEVEL VS HPE 
MORE THAN 35 LESS THAN 35
                                                        
LOCULARITY 
 
LOCULARITY NO OF PATIENTS PERCENTAGE 
MULTILOCULAR 40 80% 
UNILOCULAR 10 20% 
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MULTILOCULAR
UNILOCULAR
                                                        
LOCULARITY VS HPE 
LOCULARITY MALIGNANT BENIGN 
MULTILOCULAR 10 30 
UNILOCULAR 0 10 
   CHI SQUARE TEST 
P VALUE - 0.077 
NON SIGNIFICANT 
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SOLID AREAS 
 
SOLID AREAS NO OF PATIENTS PERCENTAGE 
PRESENT 19 38% 
ABSENT 31 62% 
 
 
 
 
 
 
 
38% 
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PRESENT
ABSENT
                                                        
SOLID AREAS VS HPE 
SOLID AREAS MALIGNANT BENIGN 
PRESENT 10 9 
ABSENT 0 31 
   CHI SQUARE TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
In ovarian tumors with solid areas in ultrasonography 10 patients had malignancy when it 
is compared with histopathological examination reports. Significant  
P value is 0.001. 
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M A L I G N A N T  B E N I G N  
SOLID AREAS VS HPE 
PRESENT ABSENT
                                                        
ASCITES 
 
ASCITES NO OF PATIENTS PERCENTAGE 
PRESENT 19 38% 
ABSENT 31 62% 
 
 
 
 
This table compares relationship of malignant tumors in patients with ascites in 
comparison to histopathological reports.  
 
38% 
62% 
ASCITES 
PRESENT
ABSENT
                                                        
 
ASCITES VS HPE 
ASCITES MALIGNANT BENIGN 
PRESENT 8 11 
ABSENT 2 29 
   CHI SQUARE TEST 
P VALUE - 0.002 
SIGNIFICANT 
 
 
In my study 8 patients with ascites histopathological report positive for malignancy. 
Significant p value is 0.002. 
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M A L I G N A N T  B E N I G N  
ASCITES VS HPE 
PRESENT ABSENT
                                                        
METASTASIS 
 
METASTASIS NO OF PATIENTS PERCENTAGE 
PRESENT 10 20% 
ABSENT 40 80% 
 
 
 
 
 
 
 
20% 
80% 
METASTASIS 
PRESENT
ABSENT
                                                        
 
METASTASIS VS HPE 
METASTASIS MALIGNANT BENIGN 
PRESENT 10 0 
ABSENT 0 40 
   CHI SQUARE TEST 
P VALUE - 0.000 
SIGNIFICANT 
 
 
 
Out of 50 patients, 10 patients with metastasis, histopathology reports positive for 
malignancy. P value is 0.000. 
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M A L I G N A N T  B E N I G N  
METASTASIS VS HPE 
PRESENT ABSENT
                                                        
                                                        SYMPTOMS 
 
SYMPTOMS NO OF PATIENTS PERCENTAGE 
ABDOMINAL PAIN 14 28% 
ABDOMINAL MASS 4 8% 
ABDOMINAL DISTENSION 14 28% 
ASYMPTOMATIC 18 36% 
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SYMPTOMS 
ABDOMINAL PAIN
ABDOMINAL MASS
ABDOMINAL DISTENSION
ASYMPTOMATIC
                                                        
SYMPTOMS VS HPE 
SYMPTOMS MALIGNANT BENIGN 
ABDOMINAL PAIN 5 9 
ABDOMINAL MASS 0 4 
ABDOMINAL DISTENSION 5 9 
ASYMPTOMATIC 0 18 
KRUSKAL  WALLIS TEST 
P VALUE - 0.020 
SIGNIFICANT 
 
 
 
Out of 50 patients, 5 patients with abdominal pain and 5 patients with abdominal 
distension, positive for malignant ovarian tumor. Significant p value is 0.020.  
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M A L I G N A N T  B E N I G N  
SYMPTOM & HPE 
ABDOMINAL PAIN ABDOMINAL MASS
ABDOMINAL DISTENSION ASYMPTOMATIC
                                                        
HISTORY OF OCP INTAKE 
 
H/O OCP INTAKE NO OF PATIENTS PERCENTAGE 
PRESENT 9 18% 
ABSENT 41 82% 
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H/O OCP INTAKE VS HPE 
H/O OCP INTAKE MALIGNANT BENIGN 
PRESENT 0 9 
ABSENT 10 31 
   CHI SQUARE TEST 
P VALUE - 0.098 
NON SIGNIFICANT 
 
 
In my study there is no significant relationship between oral contraceptive pills intake 
and incidence of malignant ovarian tumors. 
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RISK OF MALINANCY INDEX 
RMI 1 
 
RMI 1 NO OF PATIENTS PERCENTAGE 
MALIGNANT 31 62% 
BENIGN 19 38% 
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RMI 1 VS HPE 
RMI 1 MALIGNANT BENIGN 
MALIGNANT 10 21 
BENIGN 0 19 
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RMI 1 RESULT 
SENSITIVITY 100% 
SPECIFICITY 47.50% 
POSITIVE PREDICTIVE VALUE 32.26% 
NEGATIVE PREDICTVE VALUE 100% 
ACCURACY 58% 
 
Based on scoring by RMI 1, 62% had malignant ovarian tumors, 38% had benign ovarian 
tumors. After RMI 1 scoring results are compared with histopathological reports only 10 
patients had positive correlation with histopathological reports. In 21 patients 
histopathological report comes as benign but RMI 1 scoring it is belonging to malignant 
ovarian tumors. RMI 1 scoring system has sensitivity of 100%, specificity of 47.5%, 
accuracy of 58 % to differentiate benign and malignant ovarian tumors.  
 
RMI 2 
 
RMI 2 NO OF PATIENTS PERCENTAGE 
MALIGNANT 29 58% 
BENIGN 21 42% 
 
                                                        
 
 
 
 
RMI 2 VS HPE 
RMI 2 MALIGNANT BENIGN 
MALIGNANT 10 19 
BENIGN 0 21 
 
58% 
42% 
RMI 2 
MALIGNANT
BENIGN
                                                        
 
 
RMI 2 RESULT 
SENSITIVITY 100% 
SPECIFICITY 52.50% 
POSITIVE PREDICTIVE VALUE 34.48% 
NEGATIVE PREDICTV VALUE 100% 
ACCURACY 62% 
 
Based on scoring by RMI 2,58% had malignant ovarian tumors, 42% had benign 
ovarian tumors. After RMI 2 scoring results are compared with histopathological reports 
only 10 patients had positive correlation with histopathological reports. In 19 patients 
histopathological report comes as benign but RMI 2 scoring it is belonging to malignant 
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M A L I G N A N T  B E N I G N  
RMI 2 VS HPE 
MALIGNANT BENIGN
                                                        
ovarian tumors. RMI 2 scoring system has sensitivity of 100%, specificity of 52.5% , 
accuracy of 62 % to differentiate benign and malignant ovarian tumors.  
 
 
 
COMPARISON OF RMI 1 AND RMI 2 
 
 
RMI 1 RMI 2 
SENSITIVITY 100% 100% 
SPECIFICITY 47.50% 52.50% 
POSITIVE PREDICTIVE VALUE 32.26% 34.48% 
NEGATIVE PREDICTV VALUE 100% 100% 
ACCURACY 58% 62% 
 
 
                                                        
 
              Based on correlation between RMI 1 and RMI 2 to differentiate between benign 
and malignant ovarian tumors, RMI 2 is better than RMI 1 to detect malignant ovarian 
tumors in the specificity of 52.5% and accuracy of 62%.  
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                                                                                                             DISCUSSION  
                                                        
        RMI is a simple scoring system, its application to evaluate ovarian tumors 
recommended in clinical practice. In my study cut off for RMI one and two was 200.  
         Ulusoy et al reported that an RMI cut off 153, there was increased incidence of 
malignant ovarian tumors detected.  
         90% of ovarian tumors diagnosed were found to be benign tumor and rest of the 
tumors was malignant ovarian tumor. Abdominal pain and abdominal distension was the 
common presenting symptoms, a significant proportion of patients were asymptomatic at 
the time of presentation.  
         Malignant ovarian tumor prevalent in women with age more than 50 years. Ascites 
is the most important clinical sign which predicts nature of the ovarian tumor. Patients 
with metastases had poor prognosis. 
         Tumor marker CA 125, at cut off level 35u/ml does not differentiate benign and 
malignant ovarian tumors. RMI scoring requires the additional use of ultrasound features. 
RMI 2 has the advantage over malignant tumor to distinguish between benign and 
malignant tumor. 
 
 
 
 
                                                        
DIFFERENCE BETWEEN RMI 1 & RMI 2  
       Feature          RMI 1         RMI 2  
Ultrasound features  
- Multilocular cyst  
- Solid areas  
- Bilateral lesions 
- Ascites  
- Intra abdominal 
metastasis  
0- None  
1 – one abnormality  
3 – two or more 
abnormality  
      0-none  
1 – one abnormality  
     4 – two or more 
abnormality 
Premenopausal  1 1 
Postmenopausal  3 4 
CA 125  U/ml U/ml 
 
RMI score calculated by using this formula:  
Ultrasound score * menopausal score* ca 125 level (u/ml) 
 
 
 
 
                                                        
                                         
 
                                                      
 
 
 
 
      
 
                                                                                                                                                                                 
       
 
 
 
 
                                                                                                          CONCLUSION 
                                                        
          From this study, the following conclusions have been arrived. Among the various 
factors as mentioned which influence the incidence of ovarian tumors, seven factors only 
significantly related to malignant ovarian tumors.  
1. Out of 27 patients with age >50 years, 10 patients had malignant ovarian tumors.  
2. Out of 29 postmenopausal patients, 10 patients had malignant ovarian tumors. 
None of the premenopausal women had malignant ovarian tumors. 
3. Out of 18 patients with solid areas in ultrasonography, 10 patients had malignant 
ovarian tumors.   
4. Out of 50 patients, 19 patients had ascites in which 8 patients had 
histopathological report positive for malignancy.  
5. Out of 50 patients, 10 patients had metastasis for them histopathological report 
comes as malignant ovarian tumor.  
6. Out of 14 patients with abdominal pain and abdominal distension, 9 patients had 
benign ovarian tumors, 5 patients had malignant ovarian tumors.  
7. RMI 2 is better than RMI 1 to differentiate benign and malignant ovarian tumors 
with sensitivity of 100%, specificity of 52.5%, positive predictive value of 
34.48%, negative predictive value of 100%, accuracy of 62%.  
 
                                                                      
 
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                    SUMMARY                         
                                                        
RMI scoring system is a simplest and cheapest method to differentiate benign and 
malignant ovarian tumor. Based on this scoring system patients refereed to 
gynaecological oncologist for expert management. This scoring system helps us in 
determining need for surgery. Appropriate care can be given for patients with 
gynaecological cancers. Usually treatment plans are based on the type of tumor, its stage. 
If ovarian cancer treated before the cancer has sprerad survival rate is 92%. Only 15% 
ovarian cancers are found early stage. 
In my study RMI 2 scoring system has advantage over RMI 1 to identify benign 
and malignant ovarian tumor. Preoperative evaluation by using this scoring system avoids 
unnecessary surgical intervention.  
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                                                                                                 PROFORMA 
                                                        
 
Name:  
Age: 
Parity:  
Menopausal status:  
Chief complaints:  
Family history:  
h/o ocp’s intake:  
usg findings:  
CA 125 level:  
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                                                                                                               MASTER CHART 
                                                        
NAME AGE PARITY 
MENOPAUSAL 
STATUS 
CA 
125 
USG FINDINGS -SITE/LOCULARITY/SOLID 
AREAS/ASCITES/METASTASIS SYMPTOMS OCP 
FAMILY 
HISTORY RMI 1  RMI 2 HPE 
RANI  65 P2L2A1 POSTMENOPAUSAL 45 U/L MULTILOCULAR SOLID AREAS _ _ ABDOMINAL MASS NO NIL 151.2 180 BENIGN 
CHINNAPONNU 42 P3L3 PREMENOPAUSAL 47 B/L MULTILOCULAR _ _ _ ABDOMINAL PAIN NO NIL 195 180 BENIGN 
AANDAMMAL 65 P4L4 POSTMENOPAUSAL 9.1 U/L MULTILOCULAR _ _ _ 
ABDOMINAL 
DISTENSION YES NIL 27.3 36.4 BENIGN 
RUKMANI 44 P2L2 PREMENOPAUSAL 23 B/L MULTILOCULAR _ _ _ ABDOMINAL MASS NO NIL 69 92 BENIGN 
POONGODI 45 P2L2A1 PREMENOPAUSAL 31 U/L UNILOCULAR _ _ _ ASYMPTOMATIC NO NIL 0 0 BENIGN 
ROSSY 60 P6L6 POSTMENOPAUSAL 132 U/L MULTILOCULAR _ ASCITES _ 
ABDOMINAL 
DISTENSION YES NIL 1188 2112 BENIGN 
THULASIYAMMAL 50 P4L4 PREMENOPAUSAL 27.1 B/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 81.3 108.4 BENIGN 
KALEESHWARI 47 P3L2 PREMENOPAUSAL 89 U/L UNILOCULAR _ _ _ ASYMPTOMATIC NO NIL 0 0 BENIGN 
DEVI 42 P2L2 PREMENOPAUSAL 32 B/L MULTILOCULAR _ _ _ ABDOMINAL PAIN NO NIL 32 32 BENIGN 
HABIBUN NISHA  46 P3L3 PREMENOPAUSAL 28 B/L UNILOCULAR _ _ _ ASYMPTOMATIC YES NIL 28 28 BENIGN 
PADMAVATHY 73 P5L5 POSTMENOPAUSAL 717 U/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS 
ABDOMINAL 
DISTENSION NO NIL 6493 11472 MALIGNAN
NAGAMMAL 45 P4L2 PREMENOPAUSAL 35 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 35 35 BENIGN 
MAYILAMMAL 55 P3L3 POSTMENOPAUSAL 149.3 U/L MULTILOCULAR SOLID AREAS ASCITES _ 
ABDOMINAL 
DISTENSION NO NIL 1343 2388 BENIGN 
VEERAMMAL 50 P2L2 POSTMENOPAUSAL 92 U/L MULTILOCULAR SOLID AREAS _ _ ASYMPTOMATIC YES NIL 828 1472 BENIGN 
PARVATHY  52 P2L2A1 POSTMENOPAUSAL 112 B/L MULTILOCULAR SOLID AREAS ASCITES _ ABDOMINAL MASS NO NIL 1008 1792 BENIGN 
SATHYABAMA 65 P6L4 POSTMENOPAUSAL 512 B/L MULTILOCULAR SOLID AREAS ASCITES _ ABDOMINAL MASS NO NIL 4608 8192 BENIGN 
NAGARANI 64 P2L2A2 POSTMENOPAUSAL 448 B/L MULTILOCULAR SOLID AREAS ASCITES _ ABDOMINAL PAIN YES NIL 4032 7168 BENIGN 
NAGAMANI 45 P2L2 PREMENOPAUSAL 123 B/L UNILOCULAR _ _ _ ASYMPTOMATIC YES NIL 123 123 BENIGN 
PALANAL  60 P3L2A1 POSTMENOPAUSAL 142 B/L MULTILOCULAR _ ASCITES _ 
ABDOMINAL 
DISTENSION NO NIL 1278 2272 BENIGN 
NAGAMANI  50 P5L3A2 PREMENOPAUSAL 45 B/L UNILOCULAR _ _ _ 
ABDOMINAL 
DISTENSION NO YES 45 180 BENIGN 
PALANIYAMMAL  67 P2L2 POSTMENOPAUSAL 612 U/L MULTILOCULAR SOLID AREAS _ _ ASYMPTOMATIC NO NIL 5508 9792 BENIGN 
ANGATHAL  49 P3L3 PREMENOPAUSAL 170 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 170 170 BENIGN 
RANGATHAL  62 P4L4A1 POSTMENOPAUSAL 763 U/L MULTILOCULAR SOLID AREAS _ 
INTRAABDOMINAL 
METASTASIS ABDOMINAL PAIN NO NIL 6867 12603 MALIGNAN
GOVINDHAMMAL 50 P7L6 PREMENOPAUSAL 88 B/L MULTILOCULAR _ _ _ 
ABDOMINAL 
DISTENSION NO NIL 264 352 BENIGN 
AMMAPILLAI 51 P3L3A1 POSTMENOPAUSAL 678 B/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS 
ABDOMINAL 
DISTENSION NO NIL 6102 10848 MALIGNAN
CHELLAKUTTY 43 P2L2 PREMENOPAUSAL 102 B/L UNILOCULAR _ _ _ ASYMPTOMATIC YES NIL 102 102 BENIGN 
MALLIKA 69 P2L2 POSTMENOPAUSAL 352 B/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS PAIN ABDOMEN NO YES 3168 5632 MALIGNAN
RANI  62 P3L3 POSTMENOPAUSAL 355 U/L MULTILOCULAR _ ASCITES _ ABDOMINAL PAIN NO NIL 3195 5680 BENIGN 
PREMAVATHY 47 P3L2 PREMENOPAUSAL 75 B/L UNILOCULAR _ _ _ ASYMPTOMATIC YES NIL 75 75 BENIGN 
VASANTHAKUMARI 52 P2L2 POSTMENOPAUSAL 606 B/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS 
ABDOMINAL 
DISTENSION NO NIL 5454 9696 MALIGNAN
AMSAVENI 61 P3L3 POSTMENOPAUSAL 268 B/L MULTILOCULAR _ ASCITES _ ASYMPTOMATIC NO NIL 2412 4288 BENIGN 
ALAMELU  55 P2L2 POSTMENOPAUSAL 889 U/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS PAIN ABDOMEN NO NIL 8001 14224 MALIGNAN
BHUVANESHWARI 49 P2L2A1 PREMENOPAUSAL 99 B/L UNILOCULAR _ _ _ ASYMPTOMATIC NO NIL 99 99 BENIGN 
CHITHRA 42 P2L2 PREMENOPAUSAL 146 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC YES NIL 146 146 BENIGN 
MONIKAMARY 53 A1 POSTMENOPAUSAL 1088 B/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS 
ABDOMINAL 
DISTENSION NO YES 9792 17408 MALIGNAN
SUSILA 60 NULLIGRAVIDA POSTMENOPAUSAL 365 U/L MULTILOCULAR _ _ _ PAIN ABDOMEN NO NIL 1095 1460 BENIGN 
LATHA 48 P2L2 PREMENOPAUSAL 189 B/L UNILOCULAR _ _ _ ABDOMINAL PAIN NO NIL 189 189 BENIGN 
SENBAGAVALLI 63 P4L4 POSTMENOPAUSAL 560 U/L MULTILOCULAR SOLID AREAS _ 
INTRAABDOMINAL 
METASTASIS 
ABDOMINAL 
DISTENSION NO NIL 5040 8960 MALIGNAN
LAKSHMI 54 P2L2A1 POSTMENOPAUSAL 309 B/L UNILOCULAR SOLID AREAS ASCITES _ 
ABDOMINAL 
DISTENSION NO NIL 2781 4944 BENIGN 
PUSHPA 48 P5L3 PREMENOPAUSAL 108 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 108 108 BENIGN 
SHANTHI  59 P2L2 POSTMENOPAUSAL 654 U/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS PAIN ABDOMEN NO NIL 5886 10464 MALIGNAN
RAJESHWARI 61 P3L3 POSTMENOPAUSAL 439 U/L MULTILOCULAR _ ASCITES _ PAIN ABDOMEN NO NIL 3951 7024 BENIGN 
DHANALAKSHMI 57 P3L2 POSTMENOPAUSAL 678 U/L MULTILOCULAR _ ASCITES _ ABDOMINAL PAIN NO NIL 6102 10848 BENIGN 
KALYANI 48 P2L1 PREMENOPAUSAL 134 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 134 134 BENIGN 
CHELLAMAL 56 P3L3 POSTMENOPAUSAL 389 B/L MULTILOCULAR _ _ _ 
ABDOMINAL 
DISTENSION NO NIL 3501 6224 BENIGN 
                                                        
 
 
 
 
VALLI 66 P4L4 POSTMENOPAUSAL 998 B/L MULTILOCULAR SOLID AREAS ASCITES 
INTRAABDOMINAL 
METASTASIS ABDOMINAL PAIN NO NIL 8982 15968 MALIGNAN
KUPPAYI 49 P3L2A1 PREMENOPAUSAL 332 U/L MULTILOCULAR _ _ _ PAIN ABDOMEN NO NIL 332 332 BENIGN 
KANNIYAMMAL 54 P1L1 POSTMENOPAUSAL 271 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 813 1084 BENIGN 
PADMAVATHY 48 P2L2 PREMENOPAUSAL 74 U/L MULTILOCULAR _ _ _ ASYMPTOMATIC NO NIL 74 74 BENIGN 
VALARMATHI 60 P3L3 POSTMENOPAUSAL 289 B/L MULTILOCULAR SOLID AREAS _ _ 
ABDOMINAL 
DISTENSION NO YES 2601 4624 BENIGN 
